Paul J Isaac bought $45k of STXS
director, other at Stereotaxis, Inc.. 24,788 shares at an average of $1.81, traded Mar 6, 2025, filed Mar 10, 2025.
Score components
- +15RoleDirector
- +6Trade size$45k at market
- +10Relative to holdingsHoldings up 96%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001062993-25-004997, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 6, 2025 | POpen-market purchase Common stock | +23,299 | $1.81 | $42k | 49,066 | Mar 10, 2025 |
| Mar 7, 2025 | POpen-market purchase Common stockindirect: See Footnote | +1,489 | $1.79 | $2,665 | 2,766,557 | Mar 10, 2025 |
Related signals
Other insiders at Stereotaxis, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | STXSbuy Stereotaxis, Inc. | Paul J Isaac director, other | $67k 30,000 shares | +1% | |
| 38Weak | STXSbuy Stereotaxis, Inc. | Paul J Isaac director, other | $69k 38,000 shares | +77% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.